Koenig Sheldon L. sold (to issuer) 2,121,094 shares of ESPR
Koenig Sheldon L. (President and CEO) sold (to issuer) 2,121,094 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
How this was made
The 30-second read
Why it matters
The CEO’s sale to the issuer reduces his direct holdings to zero shares, but the filing provides no price or total value and no other corporate catalyst.
Market read
Traders may monitor for follow-on insider activity, but this single Form 4 lacks the datapoints needed for a strong fundamental re-rating.
What to watch
No 10b5-1 plan is cited, but the price and total value are not disclosed, limiting inference about motivation or magnitude versus typical insider behavior.
Background
The article is an SEC Form 4 insider transaction disclosure for Esperion Therapeutics, Inc.
Ticker impact
Esperion Therapeutics CEO Sheldon Koenig sold 2,121,094 shares to the issuer in an SEC Form 4 transaction filed today.
Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.
The filing is primary-source and same-day, but the transaction details lack price/value and there is no accompanying corporate event or guidance change.
Market effects
No direct sector read-across; this is company-specific insider activity only.
None indicated.
None indicated.
Counterpoint
A sale to the issuer can be part of planned liquidity or compensation mechanics, so it may not signal reduced confidence.
Key entities
- issuerEsperion Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderSheldon L. Koenig
President and CEO who sold 2,121,094 shares to the issuer.